A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.

Autor: Huang J; Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri. Electronic address: jiayi.huang@wustl.edu., Campian JL; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota., DeWees TA; Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri; Department of Computational and Quantitative Medicine, Radiation Oncology, Surgery, Division of Biostatistics, City of Hope, Duarte, California., Skrott Z; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic., Mistrik M; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic., Johanns TM; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri., Ansstas G; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri., Butt O; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri., Leuthardt E; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Department of Neurological Surgery, Washington University School of Medicine, St Louis, Missouri., Dunn GP; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Department of Neurological Surgery, Washington University School of Medicine, St Louis, Missouri., Zipfel GJ; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Department of Neurological Surgery, Washington University School of Medicine, St Louis, Missouri., Osbun JW; Department of Neurological Surgery, Washington University School of Medicine, St Louis, Missouri., Abraham C; Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri., Badiyan S; Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri., Schwetye K; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri., Cairncross JG; Clark H. Smith Brain Tumour Centre, Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Rubin JB; Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri; Department of Neuroscience, Washington University School of Medicine, St Louis, Missouri., Kim AH; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Department of Neurological Surgery, Washington University School of Medicine, St Louis, Missouri., Chheda MG; Brain Tumor Center, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Nov 01; Vol. 120 (3), pp. 738-749. Date of Electronic Publication: 2024 May 19.

Clinical Neuropathological Conference: There’s a Child in All of Us

Autor: Cynthia Hawkins, Matthew Hebb, Robert Hammond, Andrew Leung, Cairncross Jg, Alan Chalil

Publikováno v: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. :1-5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e020c90717c7b6aba086f10c56c33b
https://doi.org/10.1017/cjn.2021.24

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.

Autor: Lassman AB; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.; Herbert Irving Comprehensive Cancer Center, New York, NY.; NewYork-Presbyterian Hospital, New York, NY., Hoang-Xuan K; AP-HP, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2, Paris, France., Polley MC; NRG Oncology Statistics and Data Management Center, Philadelphia, PA., Brandes AA; Department of Medical Oncology, AUSL/IRCCS Institute of Neurological Sciences, Bologna, Italy., Cairncross JG; Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Kros JM; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands., Ashby LS; Barrow Neurological Institute, Phoenix, AZ., Taphoorn MJB; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Neurology, Haaglanden Medical Center, the Hague, the Netherlands., Souhami L; Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada., Dinjens WNM; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands., Laack NN; Mayo Clinic Accruals for Rochester Methodist Hospital, Rochester, MN., Kouwenhoven MCM; Department of Neurology, Amsterdam Universities Medical Centers, location VUmc, Amsterdam, the Netherlands., Fink KL; Baylor University Medical Center, Houston, TX., French PJ; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Macdonald DR; London Regional Cancer Program, Western University, London, Canada (RT)., Lacombe D; EORTC, Brussels, Belgium., Won M; NRG Oncology Statistics and Data Management Center, Philadelphia, PA., Gorlia T; EORTC, Brussels, Belgium., Mehta MP; Miami Cancer Institute, Miami, FL., van den Bent MJ; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Aug 10; Vol. 40 (23), pp. 2539-2545. Date of Electronic Publication: 2022 Jun 22.

Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial.

Autor: Song AJ; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Ding K; Department of Public Health Sciences, Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Alnahhas I; Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Laperriere NJ; Department of Radiation Oncology, Princess Margaret Cancer Center, Toronto, Ontario, Canada., Perry J; Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada., Mason WP; Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Winch C; Department of Public Health Sciences, Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., O'Callaghan CJ; Department of Public Health Sciences, Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Menten JJ; Department of Experimental Radiation Oncology, University Hospitals Leuven, Leuven, Belgium., Brandes AA; Department of Medical oncology, IRCCS Istituto Scienze Neurologiche - Bologna, Italy., Phillips C; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Fay MF; Genesis Cancer Care, Newcastle, NSW, Australia., Nishikawa R; Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Japan., Osoba D; QOL Consulting, West Vancouver, British Columbia, Canada., Cairncross JG; Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada., Roa W; Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada., Wick W; Division of Neurology, Heidelberg University Medical Center, Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany., Shi W; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2022 Jan 27; Vol. 4 (1), pp. vdac011. Date of Electronic Publication: 2022 Jan 27 (Print Publication: 2022).

Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer.

Autor: Nikolic A; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Singhal D; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Ellestad K; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Johnston M; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Shen Y; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada., Gillmor A; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Morrissy S; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Cairncross JG; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Jones S; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada., Lupien M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.; Ontario Institute for Cancer Research, Toronto, ON, Canada., Chan JA; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Neri P; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Bahlis N; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Gallo M; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Publikováno v: Science advances [Sci Adv] 2021 Oct 15; Vol. 7 (42), pp. eabg6045. Date of Electronic Publication: 2021 Oct 13.